Dompe Farmaceutici Patent-Cliff Exposure & CMS Drug Spending Portfolio

Dompe Farmaceutici (US): 1 reconciled FDA prescription therapies, $781.6M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$781.6M
2024 Medicare Part D Spend$714.5M
2024 Medicaid Spend$67.1M
California HCAI SB 17 Filings2 WAC filings (max 19.0% 2-yr change)